FLT1 anticorps (AA 1-380)

N° du produit ABIN6243861

Détail du produit anti-FLT1 anticorps

Antigène: FLT1 (Fms-Related tyrosine Kinase 1 (VEGFR1) (FLT1))

Épitope: AA 1-380

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp FLT1 est non-conjugé

Application: Western Blotting (WB)

Purification: This antibody is purified through a protein G column, followed by dialysis against PBS.

Immunogène: This FLT1 antibody is generated from a mouse immunized with a recombinant protein.

Clone: 1453CT519-277-79

Isotype: IgG1 kappa

Information d'application

Indications d'application: WB: 1:2000. WB: 1:2000

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Purified monoclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Date de péremption: 6 months

Détails sur FLT1

Antigène: FLT1 (Fms-Related tyrosine Kinase 1 (VEGFR1) (FLT1))

Autre désignation: FLT1 (FLT1 Produits)

Sujet: Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. May play an essential role as a negative regulator of embryonic angiogenesis by inhibiting excessive proliferation of endothelial cells. Can promote endothelial cell proliferation, survival and angiogenesis in adulthood. Its function in promoting cell proliferation seems to be cell-type specific. Promotes PGF-mediated proliferation of endothelial cells, proliferation of some types of cancer cells, but does not promote proliferation of normal fibroblasts (in vitro). Has very high affinity for VEGFA and relatively low protein kinase activity, may function as a negative regulator of VEGFA signaling by limiting the amount of free VEGFA and preventing its binding to KDR. Likewise, isoforms lacking a transmembrane domain, such as isoform 2, isoform 3 and isoform 4, may function as decoy receptors for VEGFA. Modulates KDR signaling by forming heterodimers with KDR. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, leading to activation of phosphatidylinositol kinase and the downstream signaling pathway. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Phosphorylates SRC and YES1, and may also phosphorylate CBL. Isoform 1 phosphorylates PLCG. Promotes phosphorylation of AKT1 at 'Ser-473'. Promotes phosphorylation of PTK2/FAK1. Isoform 7 has a truncated kinase domain, it increases phosphorylation of SRC at 'Tyr-418' by unknown means and promotes tumor cell invasion.

Poids moléculaire: 150769

UniProt: P17948

Pathways: Signalisation RTK, Signaling Events mediated by VEGFR1 and VEGFR2, VEGFR1 Specific Signals